Neurogene
NGNE
88 hedge funds and large institutions have $368M invested in Neurogene in 2024 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 25 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
2% more funds holding
Funds holding: 86 → 88 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
29.9% less ownership
Funds ownership: 106.6% → 76.7% (-30%)
37% less capital invested
Capital invested by funds: $581M → $368M (-$213M)
44% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $5.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$28.7M |
| 2 |
CC
Commodore Capital
New York
|
+$22.3M |
| 3 |
JP Morgan Chase
New York
|
+$17.7M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$16.7M |
| 5 |
DM
Deerfield Management
New York
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$29.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.9M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.8M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$7.38M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACA
101
Avoro Capital Advisors
New York
| – | -$924K | -22,029 | Closed |
|
102
Marshall Wace
London,
United Kingdom
| – | -$419K | -9,980 | Closed |
|
103
Stifel Financial
St. Louis,
Missouri
| – | -$388K | -9,249 | Closed |
|
104
Jane Street
New York
| – | -$287K | -7,717 | Closed |
|
105
Franklin Resources
San Mateo,
California
| – | -$351K | -7,050 | Closed |
|
106
SG Americas Securities
New York
| – | -$150K | -3,576 | Closed |
|
|
A
107
AlphaQuest
New York
| – | -$53.7K | -1,279 | Closed |
|
|
ACM
108
ADAR1 Capital Management
Austin,
Texas
| – | -$23.2K | -553 | Closed |
|
109
Acadian Asset Management
Boston,
Massachusetts
| – | -$18K | -449 | Closed |
|
110
Comerica Bank
Dallas,
Texas
| – | -$1.68K | -40 | Closed |
|
111
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$1.09K | -26 | Closed |
|
|
SAM
112
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$403 | -10 | Closed |
|
113
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$378 | -9 | Closed |
|
114
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$74 | -2 | -50% |
|
NGNE Hedge Fund Activity: Q4 2024 in Review
88 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2024, worth a combined $368M — down 37% from $581M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new NGNE positions and 25 closed out — a net gain of 3 holders — while 30 added to existing stakes and 17 trimmed.
The largest buyer was Casdin Capital, adding an estimated $28.7M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $29.8M sold.
- 88 institutional investors held Neurogene (NGNE) as of Q4 2024, up from 86 in Q3 2024.
- Funds reported $368M of Neurogene stock for Q4 2024, down 37% quarter-over-quarter.
- 28 funds opened new Neurogene positions in Q4 2024 and 25 closed out, a net change of +3 holders.
- The largest Neurogene buyer in Q4 2024 was Casdin Capital, an estimated $28.7M added.
- The largest Neurogene seller in Q4 2024 was Janus Henderson Group, an estimated $29.8M sold.
Based on aggregated 13F filings for Q4 2024.